zanolimumab: Clinical Trials

5 trials of zanolimumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated. 5 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Terminated 2
Phase 32Completed 1, Terminated 1

Follow zanolimumab: new trials by email Literature Review of zanolimumab trials Research Report on zanolimumab

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Zanolimumab, Aldesleukin - Metastatic Melanoma, Metastatic Renal Cancer
Phase 2TerminatedNational Cancer Institute (NCI)92010-06-012015-10-28
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
HuMax-CD4 - T Cell Lymphoma
Phase 2 / Phase 3CompletedEmergent BioSolutions212005-08-012024-03-18
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
HuMax-CD4 - Cutaneous T-Cell Lymphoma
Phase 2CompletedGenmab222003-05-272023-04-28
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
HuMax-CD4 - Cutaneous T-Cell Lymphoma
Phase 2CompletedGenmab252003-04-302023-05-18
Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker
HuMax-CD4, Placebo, Humax-CD4 - Rheumatoid Arthritis
Phase 2 / Phase 3TerminatedGenmab832002-03-042023-04-28

Conditions studied

Lymphoma (2)  ·  Lymphoma, T-Cell, Cutaneous (2)  ·  Mycosis Fungoides (2)  ·  Sezary Syndrome (2)  ·  Skin Neoplasms (2)  ·  Arthritis, Rheumatoid (1)  ·  Kidney Neoplasms (1)  ·  Lymphoma, T-Cell (1)  ·  Melanoma (1)

Sponsors

Genmab (3)  ·  Emergent BioSolutions (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (4)  ·  Canada (1)  ·  Germany (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Abhay Patki, PhD (1)  ·  David S Schrump, M.D. (1)